key: cord-0696493-2zxaih4r authors: Greasley, Samantha E; Noell, Stephen; Plotnikova, Olga; Ferre, RoseAnn; Liu, Wei; Bolanos, Ben; Fennell, Kimberly; Nicki, Jennifer; Craig, Tim; Zhu, Yuao; Stewart, Al E; Steppan, Claire M title: Structural basis for Nirmatrelvir in vitro efficacy against the Omicron variant of SARS-CoV-2 date: 2022-01-19 journal: bioRxiv DOI: 10.1101/2022.01.17.476556 sha: 4ce4a9affc15ad46a99d05be98ded1b9afe220dd doc_id: 696493 cord_uid: 2zxaih4r The COVID-19 pandemic continues to be a public health threat with emerging variants of SARS-CoV-2. Nirmatrelvir (PF-07321332) is a reversible, covalent inhibitor targeting the main protease (Mpro) of SARS-CoV-2 and the active protease inhibitor in PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets). One of the predominant SARS-CoV-2 variants emerging is the B.1.1.529 Omicron harboring a mutation at amino acid position 132 in the Mpro changing a proline to a histidine (P132H). In vitro biochemical enzymatic assay characterization of the enzyme kinetics of the Omicron Mpro (P132H) demonstrate that it is catalytically comparable to wildtype and that nirmatrelvir has similar potency against both wildtype and Omicron (P132H) Mpro with Ki of 0.933nM (wildtype) and 0.635nM (P132H) each, respectively. This observation is reinforced by our structural determination of nirmatrelvir bound to the omicron Mpro at 1.63Å resolution. These in vitro data suggest that PAXLOVID has the potential to maintain plasma concentrations of nirmatrelvir many-fold times higher than the amount required to stop the SARS-CoV-2 variant Omicron from replicating in cells. SARS-CoV-2 is a highly infectious, ribonucleic acid (RNA) beta coronavirus that can be lifethreatening in serious cases. While effective COVID-19 vaccines have been developed, a significant number of people have yet to be vaccinated -either because of pre-existing medical conditions, vaccination hesitancy or challenges with access. Therefore, therapeutics are needed to effectively combat coronavirus disease 2019 . (5) The SARS-CoV-2 genome encodes two polyproteins (pp1a and pp1ab) and four structural proteins (5) . The polyproteins are cleaved by the critical SARS-CoV-2 main protease (M pro , also referred to as 3CL protease) at eleven different sites to yield shorter, non -structural proteins vital to viral replication (5) . We have previously reported on the discovery and antiviral efficacy of nirmatrelvir (PF-07321332), an orally bioavailable SARS-CoV-2-M pro inhibitor with in vitro pan-human coronavirus antiviral activity with excellent off-target selectivity and in vivo saf ety profiles (5) . Nirmatrelvir has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations that exceed the in vitro antiviral cell potency, in a phase I clinical trial in healthy subjects (5) . With Omicron being a dominant variant of concern, we evaluated the biochemical potency of nirmatrelvir against the M pro harboring a mutation at P132 which exists in Omicron. We demonstrate that nirmatrelvir has a comparable potency against the Omicron protease relative to wildtype (M pro from the original Washington variant (USA-WA1/2020). This observation is reinforced by our structural determination of nirmatrelvir bound to the omicron protease at 1.63 Å resolution ( Figure 2 ). Full-length wildtype SARS-CoV-2 M pro and Omicron P132H were expressed and purified to near homogeneity as demonstrated by a singular protein peak with a confirmed intact mass of 33.8 kDa for a fully authentic form of each protein. (Figure 1A) . Briefly, the wild type SARS-Cov2-M pro construct was designed based on Su et al 2020 (6) . An additional N-terminal PreScission protease cleavage site was inserted between GST and the self -cleavage site. Site directed mutagenesis was performed to make the P132H variant. The resulting plasmid was then transformed into BL21 (DE3) cells for protein expression. One liter of LB media was inoculated with 30mL of overnight culture and grown at 37°C until an OD 600 of 0.6 was reached. The culture was induced using a final concentration of 0.2 mM IPTG and harvested 1 hour post induction. Cells were lysed in 20 mM Tris pH 8.0 buffer containing 500 mM NaCl, 10% glycerol, 0.2 mM TCEP with a microfluidizer, and the mixture was clarified by centrifugation at 15000 x g. The resulting supernatant was purified by a Ni-affinity column using a step gradient, followed by C-terminal His-tag cleavage with PreScission protease, and a secondary Ni-affinity purification to remove non-cleaved M pro and PreScission protease. A final and size exclusion chromatography step showed the M pro P132H protein to be nearly 100% pure ( Figure 1B ). An established M pro fluorescence resonance energy transfer (FRET)-based cleavage assay was used to determine enzyme catalytic activity by monitoring initial velocities of the proteolytic activities at varying substrate (SARS canonical peptide) concentrations (5,7,8) ( Figure 1C ). The turnover number (kcat) was determined to be 0.41 ± 0.144 s -1 for the wildtype M pro and 0.39 ± 0.152 s -1 for the P132H M pro omicron variant. Additionally, the Michaelis constants (Km) were comparable for both WT and P132H with values of 23.4 and 25.5 mM, respectively. The catalytic efficiencies (kcat/Km) of the P132H variant (22691 S -1 M -1 ) is similar to wildtype M pro (22411S -1 M -1 ). These data suggest that the Omicron variant M pro exhibits comparable enzymatic properties as compared to wildtype M pro . Next, we evaluated the ability of nirmatrelvir to inhibit both wildtype and P132H M pro activity ( Figure 1D ). Nirmatrelvir potently inhibited both wildtype with a mean Ki of 0.93 nM and the mutated enzyme containing the P132H substitution with a mean Ki of 0.64 nM (Table 1) . A comparison of the P132H mutated enzyme potency to that of wildtype M pro by t-Test using the log of individual Ki values with one tail and un-equal variance determined a p-value of 0.07 indicating that the Ki values are not statistically different. These observations are consistent with recently reported biochemical characterization with similar kcat/Km and nirmatrelvir potency values (9) . Nirmatrelvir also appears to retain its in vitro antiviral efficacy against Omicron relative to wildtype (10) . The crystal structure of SARS-CoV-2 Omicron P132H M pro bound to nirmatrelvir was determined at 1.63Å. Apo crystals of SARS-CoV-2 Omicron P132H M pro were obtained via vapor diffusion in sitting drops using MRC-Maxi (Swissci) plates where protein, at 7.30 mg/ml, was mixed 1:1 with well solution containing 20% w/v polyethylene glycol (PEG) 3350 and 0.12 M sodium sulfate. Plates were incubated at 21°C and crystals grew in under 24 hours. PF-07321332 (1 mM final concentration) was added directly to the crystallization drop and allowed to soak into the apo crystals for 3 hours at 30 o C. Soaked crystals were then passed through a cryoprotectant consisting of well buffer containing 20% ethylene glycol, and flash cooled in liquid nitrogen in preparation for data collection. X-ray diffraction data were collected at -173 o C at IMCA-CAT 17-ID beamline (11, 12) of the Advanced Photon Source (APS) at Argonne National Labs (13) and the structure was determined by difference Fourier and refined using the anisotropically scaled data as described previously for wildtype SARS-CoV-2-M pro in complex with PF-07321332 (5) . Diffraction data processing and model refinement statistics for the mutant M pro are given in Table 2 . Comparison of the SARS-CoV-2 Omicron P132H M pro crystal structure to the wildtype M pro , the structure of which was reported in detail previously (5, 14) , shows that the binding mode of nirmatrelvir is the same in both structures as shown in Figure 2a . Indeed, Pro 132 is located approximately 16.5Å (C-Pro132 to C-Glu166) from the PF-07321332 binding pocket. The protein structure surrounding the mutation, P132H, remains structurally unchanged with the except of the side change conformation of Glu 240 which adopts a different rotomer to avoid a potential clash with the histadine side chain. In addition, a water molecule (Wat 1, Figure 2b ) observed in the wildtype M pro structure is displaced by the side chain of His 132. To provide an extended SARS-Cov-2 M pro structural assessment, the solution-phase structural dynamics of P132H and wildtype SARS-Cov2 M pro (10 M, 25 mM Tris pH=7.2, 150 mM NaCl) were individually profiled using HDX-MS. Native protein was deuterium exchanged at four time points (15s, 1m, 10m, 1h) , and subsequently digested with two protease columns (Protease XIII/Pepsin (NovaBioAssays) and Nepenthesin-1 (AffiPro) to generate deuterated peptides for LC-MS analysis. A total of 405 WT peptides were identified (Table 3 ) on the Fusion Lumos OrbiTrap mass spectrometer (mass tolerance <5 ppm) using Proteome Discoverer 2.2.0 software (Thermo Fisher Scientific). Residual plot (Figure 2c ) comparing WT and P132H deuterium uptake profiles (HD Examiner 3.3.0 software, Sierra Analytics) revealed no significance differences (+ 6% deuterium) in the backbone dynamics of P132H from wild-type SARS-Cov-2 M pro . These results provided the assurance that the P132H mutation alone did not produce a significant shift from wild-type solution-phase backbone conformational dynamics. The emergence of naturally occurring SARS-CoV-2 variants exemplify its ability to mutate and signify the continued potential for this pandemic to be problematic. We need to constantly surveil these emerging variants of concern to understand the efficacy of current therapies. Studies described here demonstrate the in vitro inhibitory activity of nirmatrelvir against the Omicron variant M pro and indicate the structural basis for retention of in vitro potency against this mutant protein. They also inform the methods for assessing activity against subsequent variants possessing mutations in the M pro protein. R free is the same as R cryst , but for 5% of the data randomly omitted from refinement. (17) c. d. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19 A pneumonia outbreak associated with a new coronavirus of probable bat origin Novel Coronavirus (2019-nCoV): situation report, 1. World Health Organization The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19 Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir (PF-07321332). bioRXiv 04January2022 (preprint not yet peer reviewed Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern Use of the IMCA-CAT beamline 17-ID (or 17-BM) at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman This research used resources at the Industrial Macromolecular Crystallography Association Collaborative Access Team (IMCA-CAT) beamline 17-ID, supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No Structural basis of main proteases of coronavirus bound to drug candidate PF-07321332. bioRxiv. 08November2021. (preprint, not yet peer reviewed) On the use of the merging R factor as a quality indicator for X-ray data Linking crystallographic model and data quality We thank Mark Noe, Gretchen Dean, Jake Wasserman, Annaliesa Anderson and Charlotte Allerton for critical reading of the manuscript and leadership. Competing Interest Declaration: All authors are employees of Pfizer, Inc and may hold or own shares of stock.